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Introduction
The association of alkylators with secondary hematologic
malignancies, including myelodysplastic syndromes (MDS), is
well recognized in multiple myeloma (MM).1-5 In contrast, the
potential association with lenalidomide has only recently
emerged,6-8 raising concern among physicians and patients.
However, it is still not clear whether dysplastic features are
already present at diagnosis. In fact, it has recently been report-
ed that not only MM, but also patients with monoclonal gam-
mopathy of undetermined significance (MGUS) have a higher
risk of developing AML/MDS than age-matched controls.9
Multiparameter flow cytometry (MFC) immunophenotyp-
ing is currently considered a sensitive adjuvant test in the
screening of MDS.10.11 Herein, we report a comprehensive
analysis of the distribution and immunophenotypic profile of
bone marrow (BM) hematopoietic cells in newly diagnosed
symptomatic MM and high-risk smoldering MM (SMM). In
addition, the BM of high-risk SMM cases after nine courses of
lenalidomide plus dexamethasone (Len/Dex) was also ana-
lyzed.
Design and Methods
A total of 47 myeloma (15 symptomatic and 32 SMM) patients were
studied, all diagnosed according to the International Myeloma
Working Group.12 SMM patients were categorized as high-risk accord-
ing to the presence of at least two of the three following criteria: BM
plasma cell (PC) infiltration of 10% or over; high M-component (IgG
≥ 30 g/L or IgA ≥ 20 g/L or B-J Protein > 1 g/24 h); or 95% or over MM-
PC/BMPC plus immunoparesis. SMM patients were included in the
QUIREDEX trial (NCT00480363) that compared Len/Dex versus place-
bo. BM samples were studied at baseline in 33 (15 symptomatic MM
and 18 SMM) cases. We also analyzed 22 SMM (including 8 from the
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Increased risk of acute myeloid leukemia/myelodysplastic syn-
dromes following treatment has been reported in multiple
myeloma, but whether dysplastic features are already present
at diagnosis remains to be investigated. Using multiparameter
flow cytometry, we analyzed the distribution and phenotype of
bone marrow hematopoietic cells from 47 multiple myeloma
patients (15 symptomatic and 32 high-risk smoldering). From
the 32 smoldering myeloma patients, 18 were studied at base-
line and 22 after nine cycles of lenalidomide/dexamethasone
treatment following the QUIREDEX trial (including 8 from
baseline). Phenotypic alterations of bone marrow cells of 7
(47%) symptomatic and 6 (33%) smoldering myeloma patients
were detected at baseline; there was no difference in the fre-
quency and extent of phenotypic alterations between sympto-
matic versus smoldering cases. Likewise, no difference was seen
between smoldering myeloma patients studied at baseline ver-
sus after lenalidomide/dexamethasone treatment. Our results
suggest that phenotypic alterations of bone marrow
hematopoietic cells are often present in newly diagnosed symp-
tomatic and smoldering multiple myeloma patients.
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ABSTRACT
baseline cohort) after nine cycles of Len/Dex (nine 4-week cycles
of lenalidomide at daily doses of 25 mg on Days 1–21, plus 20 mg
dexamethasone on Days 1-4 and 12-15). All BM samples were
taken after obtaining informed consent in accordance with the rec-
ommendations of the local ethics committee. The study was
approved by the relevant institutional review boards and ethics
committee.
MFC immunophenotyping was performed as previously
described10,11 using a total of 27 MoAbs in 4-color combinations to
identify and characterize BM hematopoietic cells, allowing 83 dif-
ferent phenotypic parameters to be assessed (Online Supplementary
Appendix). Only those parameters with a deviation of 3 SD or more
from reference values (defined in 40 normal/reactive BM samples)
were considered to be altered. Accordingly, patients were classified
as having "isolated alterations" (one alteration in one or more cell
lineages) and "multiple alterations" (more than one alteration in
one or more cell lineages). Patients with normal phenotypic pro-
files were categorized as "no alterations". The severity of the alter-
ations was evaluated using a previously reported immunopheno-
typic score10,11 that gives 1 or 2 points to each phenotypic parame-
ter that has a deviation from normal reference values of between
3-4 SD or over 4 SD, respectively (Online Supplementary Appendix).
The overall score for each sample was determined by the sum of
all partial scores. In SMM patients included in the QUIREDEX trial,
central morphological review of BM slides specifically for blast
count and dysplasia was performed in 17 of 18 cases at diagnosis
and in 12 cases after the nine induction cycles of Len/Dex.
Response rates in the first group were as follows: 19% achieved
(stringent and conventional) complete remission, 10% very good
partial response, 57% partial response, and 14% remained with
stable disease.
According to standard criteria, fluorescence in situ hybridization
(FISH) analyses (and not conventional karyotyping) were per-
formed on immunomagnetically enriched plasma cells.
Group differences were compared using the χ2 and Mann-
Whitney U tests for categorical and continuous variables, respec-
tively (SPSS 18.0, Chicago, IL, USA).
Results and Discussion
The survival of MM has significantly increased in the last
decade13-15 but this extended survival has also alerted physi-
cians to the potential risk of secondary MDS associated
with some drugs/regimens, particularly alkylating-based
schemes1,2 and, more recently, lenalidomide treatment.6-8 In
turn, a predisposition to an overt MDS was recently
observed in the overall MM (and MGUS) population.9
However, a comprehensive screening of dysplastic features
was not performed in newly diagnosed myeloma patients.
In the present study. "multiple phenotypic alterations" sim-
ilar to those observed in MDS patients were found at diag-
nosis in 2 of 15 (13%) symptomatic MM but not in SMM
patients (Table 1). Therefore, the incidence of dysplastic
features reported in MM after high-dose therapy/autolo-
gous stem cell transplantation (HDT/ASCT) (1-13%)1-4,16,17
could have been overestimated since some of these may
already be present at baseline.18 Interestingly, up to 20% of
all myeloma patients showed an immunophenotypic score
that is found only in MDS and not in normal/reactive BM
samples (Online Supplementary Table S1).
In addition to the aforementioned "multiple alterations",
"isolated phenotypic alterations" at baseline were found in
34% of symptomatic MM (5 of 15) and 33% of high-risk
SMM (6 of 18) cases (Table 1). It should be noted that, sim-
ilarly to the HUMARA assay, gene chip profiling, or point
mutation analysis, MFC is considered to be an adjuvant test
for the screening of MDS that may provide additional infor-
mation to the standard BM morphological and cytogenetic
evaluation. In fact, we were able to investigate the presence
of MDS-recurrent abnormalities through FISH analysis, or
the presence of clonality by the HUMARA X-chromosome
inactivation assay, on purified CD34+ cells, neutrophils, ery-
throblasts and monocytes from 3 symptomatic MM
patients showing either isolated or multiple phenotypic
alterations (2 males and one female, respectively). Our
results showed the presence of del(7q31) in both CD34+
cells and erythroblasts in one of the 2 male patients, as well
as the presence of clonality in neutrophils and monocytes
purified from the female MM patient. Future studies are
needed to replicate and expand on these observations.
Detection of multilineage BM dysplasia has been report-
ed in non-clonal cytopenic conditions (e.g. vitamin B12 and
folic acid deficiency).11,19-21 In myeloma, it could be hypoth-
esized that due to occupation of BM niches by clonal PC,
normal BM cells are expelled from their natural microenvi-
ronment,22 translating into deregulated hematopoiesis.23 If
this is the case, it would be expected that due to increasing
tumor burden, the frequency and extent of phenotypic
alterations would be slightly higher in newly diagnosed
symptomatic patients than in high-risk SMM patients.
However, detailed immunophenotypic analysis of the dif-
ferent hematopoietic BM cell compartments revealed no
significant differences in the frequency of altered CD34+
and/or CD117+ hematopoietic precursor cells, or the neu-
trophil, monocytic, B-cell, erythroid, basophil and
eosinophil lineages, except for a greater frequency of CD56+
monocytes in symptomatic MM (Table 2). These data indi-
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Table 1. Frequency of immunophenotypic alterations in bone marrow cell compartments (other than plasma cells) of patients with symptomatic
multiple myeloma (MM) and smoldering multiple myeloma (SMM) at diagnosis, and SMM cases after induction therapy with nine courses of
lenalidomide plus dexamethasone (Len/Dex).
Immunophenotypic characteristics Symptomatic MM SMM P* SMM after Len/Dex P**
of bone marrow cell compartments at diagnosis (N = 15) at diagnosis (N = 18) (N = 22)
No alterations 8 (53%) 12 (67%) 0.3 14 (64%) 0.5
Isolated alterations 5 (34%) 6 (33%) 0.7 7 (32%) 0.7
Unilineage 3 4 0.3 4 0.9
Multilineage 2 2 3
Multiple alterations 2 (13%) 0 (0%) 0.1 1 (4%) 0.4
Patients were classified as showing "isolated unilineage" (one alteration in a single cell lineage), "isolated multilineage" (one alteration in more than one cell lineage), and "mul-
tiple alterations" (more than one alteration in one or more cell lineages). Patients with normal phenotypic profiles were classified as having no alterations. BM: bone marrow; SMM:
smoldering multiple myeloma; MM: multiple myeloma; MDS: myelodysplastic syndrome. * MM vs. SMM at diagnosis, ** SMM at diagnosis vs. SMM after induction.
cate that, overall, there is no significant difference in matu-
ration patterns of BM cell compartments between sympto-
matic and smoldering MM. 
Due to recent concerns about the potential risk of second-
ary AML/MDS following lenalidomide treatment,6-8 we also
analyzed the relative distribution and phenotypic patterns
of BM cells in SMM patients after nine courses of Len/Dex.
Based on the use of lenalidomide to treat MDS,24 we should
also consider the alternative possibility of a reduction in the
number of phenotypic alterations after treatment. Overall,
no significant differences were noted between SMM
patients after treatment and the baseline cohort with
respect to the frequency and severity of the alterations
detected (as evaluated by the immunophenotypic score),
except for a trend towards increased frequency of pheno-
typically altered erythroblasts (P=0.08) (Tables 1-2 and
Online Supplementary Table S1). Similarly, no differences
were noted in the frequency of cases with mild morpholog-
ical alterations before and after Len/Dex treatment (25% vs.
18%; P=0.6). Since MDS is also characterized by cytope-
nias, we quantified the distribution of the hematopoietic
BM cell compartments by high-sensitivity MFC
immunophenotyping. Only greater numbers of erythrob-
lasts and basophils (P<0.05), and a lower (borderline signif-
icance) percentage of B cells (P=0.07) were detected after
treatment (Online Supplementary Table S2). Therefore, our
results do not suggest an association between Len/Dex and
MDS development. Likewise, Mailankody et al. recently
s. matarraz et al.
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Table 2.  Specific phenotypic alterations detected in various cell populations in patients with symptomatic multiple myeloma (MM) and smoldering
multiple myeloma (SMM) at diagnosis, as well as SMM cases after induction therapy with nine courses of lenalidomide plus dexamethasone
(Len/Dex).
Cell populations and altered N. patients with immunophenotypic aberrancies
phenotypic parameters Symptomatic MM at diagnosis SMM at diagnosis P * SMM after Len/Dex  P**
(N = 7) (N = 6) (N = 8) 
CD34+ and/or CD117+ HPC 2 (29%) 0 (0%) 0.2 1 (11%) 0.4
Maturation blockade 1 (14%) 0 0.4 1 (11%) 0.4
SSClo 0 0 0.9 0 0.9
CD56+ 2 (29%) 0 0.2 0 0.9
Neutrophil lineage 4 (80%) 4 (57%) 0.4 4 (44%) 0.2
Cy-MPOlo 0 1 (20%) 0.2 1 (11%) 0.6
SSClo 0 0 0.9 0 0.9
CD11b/CD13 pattern 2 (29%) 0 0.2 0 0.9
CD14+ 2 (29%) 2 (40%) 0.7 0 0.2
CD15/CD16 pattern 2 (29%) 1 (20%) 0.7 1 (8%) 0.4
CD34+ 0 0 0.9 0 0.9
CD56+ 2 (29%) 0 0.2 0 0.9
CD65het 0 0 0.9 0 0.9
Monocytic lineage 5 (71%) 2 (40%) 0.3 2 (22%) 0.5
CD2+ 0 1 (20%) 0.2 2 (22%) 0.9
CD11b/CD13 pattern 2 (29%) 1 (9%) 0.7 0 0.2
CD14/CD300e pattern 0 0 0.9 0 0.9
CD15/CD16 pattern 1 (14%) 0 0.4 0 0.9
CD36/CD64 pattern 0 0 0.9 0 0.9
CD56+ 5 (71%) 1 (9%) 0.02 0 0.2
Erythroid lineage 2 (29%) 0 0.2 4 (50%) 0.08
CD36- 1 (14%) 0 0.4 3 (33%) 0.1
CD71-/lo 2 (29%) 0 0.2 2 (22%) 0.2
B-cell lineage 0 (0%) 0 (0%) 0.9 0 (0%) 0.9
Cy-CD79a-/lo 0 0 0.9 0 0.9
Basophil lineage 0 (0%) 0 (0%) 0.9 0 0.9
HLA-DR+ 0 0 0.9 0 0.9
CD34+ 0 0 0.9 0 0.9
Eosinophil lineage 0 (0%) 0 (0%) 0.9 0 0.9
CD15lo 0 0 0.9 0 0.9
CD33+ 0 0 0.9 0 0.9
Median n. altered lineages 2 (1 - 4) 1 (1 - 2) 0.4 1 (1 - 2) 0.9
* SMM at diagnosis vs. SMM after induction; ** MM vs. SMM at diagnosis; -: not present; +: positive expression; het: heterogeneous expression. Results expressed as number and per-
centage (between brackets) of altered cases. SMM: smoldering multiple myeloma; MM: multiple myeloma; HPC: hematopoietic precursor cells; MPO: myeloperoxidase; SSC: sideward
light scatter; Cy: cytoplasmic
reported that the risk of AML/MDS in MM patients was
similar before and after the introduction of immunomodu-
latory agents.9
Finally, in order to better assess any potential association
between phenotypic alterations and Len/Dex treatment,
we analyzed the 8 cases for which paired immunopheno-
typic studies had been performed at diagnosis and after the
nine cycles of Len/Dex (Online Supplementary Table S3). Of
these, 7 had no alterations at diagnosis: 4 of them remained
without alterations after treatment while the other 3 devel-
oped isolated alterations. Finally, one patient with an isolat-
ed alteration up-front maintained the same phenotypic pro-
file (MPOlo expression in neutrophils) after treatment.
Our results suggest that, in a small proportion of MM
and SMM patients, phenotypic alterations, detected by
high-sensitivity MFC immunophenotyping, are already
present in BM hematopoietic cell compartments at diag-
nosis. Whether these cells are more susceptible to further
multistep accumulation of genetic defects remains to be
clarified. Finally, our results do not support either a protec-
tive or a triggering effect between Len/Dex and MDS
development.
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